BACKGROUND: Endogenous sex hormones have been related to cardiovascular outcomes and mortality. We hypothesized that sex hormones are related to atrial fibrillation (AF) in a community-based cohort of middle-aged to older men. METHODS AND RESULTS: We examined testosterone, estradiol, and dehydroepiandrosterone sulfate in relation to incident AF in men participating in the Framingham Heart Study. We assessed the 10-year risk of AF in multivariable-adjusted hazard models. The cohort consisted of 1251 men (age, 68.0±8.2 years), of whom 275 developed incident AF. We identified a significant interaction between age and testosterone and, therefore, stratified men into age 55 to 69 years (n=786), 70 to 79 years (n=351), and ≥80 years (n=114). In men aged 55 to 69 years, each 1 SD decrease in testosterone was associated with hazard ratio (HR) 1.30 (95% confidence interval [CI], 1.07-1.59) for incident AF. The association between testosterone and 10-year incident AF in men 70 to 79 years did not reach statistical significance. In men≥80 years, a 1 SD decrease in testosterone was associated with HR 3.53 (95% CI, 1.96-6.37) for AF risk. Estradiol was associated with incident AF (HR, 1.12; 95% CI, 1.01-1.26). Dehydroepiandrosterone sulfate had a borderline association with risk of AF that was not statistically significant (HR, 1.12; 95% CI, 0.99-1.28). CONCLUSIONS: Testosterone and estradiol are associated with incident AF in a cohort of older men. Testosterone deficiency in men≥80 years is strongly associated with AF risk. The clinical and electrophysiological mechanisms underlying the associations between sex hormones and AF in older men merit continued investigation.
BACKGROUND: Endogenous sex hormones have been related to cardiovascular outcomes and mortality. We hypothesized that sex hormones are related to atrial fibrillation (AF) in a community-based cohort of middle-aged to older men. METHODS AND RESULTS: We examined testosterone, estradiol, and dehydroepiandrosterone sulfate in relation to incident AF in men participating in the Framingham Heart Study. We assessed the 10-year risk of AF in multivariable-adjusted hazard models. The cohort consisted of 1251 men (age, 68.0±8.2 years), of whom 275 developed incident AF. We identified a significant interaction between age and testosterone and, therefore, stratified men into age 55 to 69 years (n=786), 70 to 79 years (n=351), and ≥80 years (n=114). In men aged 55 to 69 years, each 1 SD decrease in testosterone was associated with hazard ratio (HR) 1.30 (95% confidence interval [CI], 1.07-1.59) for incident AF. The association between testosterone and 10-year incident AF in men 70 to 79 years did not reach statistical significance. In men≥80 years, a 1 SD decrease in testosterone was associated with HR 3.53 (95% CI, 1.96-6.37) for AF risk. Estradiol was associated with incident AF (HR, 1.12; 95% CI, 1.01-1.26). Dehydroepiandrosterone sulfate had a borderline association with risk of AF that was not statistically significant (HR, 1.12; 95% CI, 0.99-1.28). CONCLUSIONS:Testosterone and estradiol are associated with incident AF in a cohort of older men. Testosterone deficiency in men≥80 years is strongly associated with AF risk. The clinical and electrophysiological mechanisms underlying the associations between sex hormones and AF in older men merit continued investigation.
Entities:
Keywords:
aging; atrial fibrillation; epidemiology; men
Authors: B Zumoff; G W Strain; L K Miller; W Rosner; R Senie; D S Seres; R S Rosenfeld Journal: J Clin Endocrinol Metab Date: 1990-10 Impact factor: 5.958
Authors: S Amin; Y Zhang; C T Sawin; S R Evans; M T Hannan; D P Kiel; P W Wilson; D T Felson Journal: Ann Intern Med Date: 2000-12-19 Impact factor: 25.391
Authors: Thomas J Wang; Helen Parise; Daniel Levy; Ralph B D'Agostino; Philip A Wolf; Ramachandran S Vasan; Emelia J Benjamin Journal: JAMA Date: 2004-11-24 Impact factor: 56.272
Authors: David E Laaksonen; Leo Niskanen; Kari Punnonen; Kristiina Nyyssönen; Tomi-Pekka Tuomainen; Veli-Pekka Valkonen; Jukka T Salonen Journal: J Clin Endocrinol Metab Date: 2004-11-09 Impact factor: 5.958
Authors: Rebecca Vigen; Colin I O'Donnell; Anna E Barón; Gary K Grunwald; Thomas M Maddox; Steven M Bradley; Al Barqawi; Glenn Woning; Margaret E Wierman; Mary E Plomondon; John S Rumsfeld; P Michael Ho Journal: JAMA Date: 2013-11-06 Impact factor: 56.272
Authors: Johan Svartberg; Denise von Mühlen; Henrik Schirmer; Elizabeth Barrett-Connor; Johan Sundfjord; Rolf Jorde Journal: Eur J Endocrinol Date: 2004-01 Impact factor: 6.664
Authors: F H Messerli; G E Garavaglia; R E Schmieder; K Sundgaard-Riise; B D Nunez; C Amodeo Journal: Ann Intern Med Date: 1987-08 Impact factor: 25.391
Authors: Neal A Chatterjee; Ravi V Shah; Venkatesh L Murthy; Amy Praestgaard; Sanjiv J Shah; Corey E Ventetuolo; R Graham Barr; Richard Kronmal; Joao A C Lima; David A Bluemke; Michael Jerosch-Herold; Alvaro Alonso; Steven M Kawut Journal: Circ Arrhythm Electrophysiol Date: 2017-01
Authors: Wesley T O'Neal; Hooman Kamel; Suzanne E Judd; Monika M Safford; Viola Vaccarino; Virginia J Howard; George Howard; Elsayed Z Soliman Journal: Am J Cardiol Date: 2017-06-15 Impact factor: 2.778
Authors: Shawn M Crump; Zhaoyang Hu; Ritu Kant; Daniel I Levy; Steve A N Goldstein; Geoffrey W Abbott Journal: FASEB J Date: 2015-09-23 Impact factor: 5.191
Authors: Yoshihiro Tanaka; Joshua D Bundy; Norrina B Allen; S M Iftekhar Uddin; David I Feldman; Erin D Michos; Susan R Heckbert; Philip Greenland Journal: Am J Med Date: 2019-11-16 Impact factor: 4.965
Authors: Michael A Rosenberg; Molly M Shores; Alvin M Matsumoto; Petra Bůžková; Leslie A Lange; Richard A Kronmal; Susan R Heckbert; Kenneth J Mukamal Journal: Clin Cardiol Date: 2018-06-08 Impact factor: 2.882
Authors: Dylan Berger; Aaron R Folsom; Pamela J Schreiner; Lin Y Chen; Erin D Michos; Wesley T O'Neal; Elsayed Z Soliman; Alvaro Alonso Journal: Maturitas Date: 2019-03-31 Impact factor: 4.342